US Stock MarketDetailed Quotes
ALLO Allogene Therapeutics
- 2.480
- +0.200+8.77%
Trading Nov 26 14:44 ET
519.99MMarket Cap-1600P/E (TTM)
2.770High2.440Low4.32MVolume2.500Open2.280Pre Close11.14MTurnover2.84%Turnover RatioLossP/E (Static)209.67MShares5.77552wk High1.12P/B376.64MFloat Cap1.99052wk Low--Dividend TTM151.87MShs Float55.000Historical High--Div YieldTTM14.47%Amplitude1.990Historical Low2.579Avg Price1Lot Size
About Allogene Therapeutics Company
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Company Profile
SymbolALLO
Company NameAllogene Therapeutics
Listing DateOct 11, 2018
Issue Price18.00
Founded2017
CEODr. David D. Chang, M.D.,PhD
MarketNASDAQ
Employees233
Fiscal Year Ends12-31
Address210 East Grand Avenue
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080-4811
Phone1-650-457-2700
Websitehttp://www.allogene.com
Company Executives
- Name
- Position
- Salary
- Dr. David D. Chang, M.D.,PhD
- Director, Chief Executive Officer and President
- 14.06M
- Geoffrey M. Parker
- Executive Vice President and Chief Financial Officer
- --
- Timothy L. Moore
- Executive Vice President and Chief Technical Officer
- 5.80M
- Dr. Zachary Roberts, M.D.,PhD
- Executive Vice President, Research and Development and Chief Medical Officer
- 8.13M
- Earl Douglas
- Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary
- --
- Annie Yoshiyama
- Principal Accounting Officer, Senior Vice President and Corporate Controller
- --
- Dr. Arie S. Belldegrun, F.A.C.S.,M.D.
- Executive Chairman of the Board
- 9.36M
- Joshua A. Kazam
- Director
- 684.49K
- Deborah M. Messemer
- Independent Director
- 495.00K
- John DeYoung
- Independent Director
- --
- Dr. Owen N. Witte, M.D.
- Independent Director
- 510.00K
- Dr. Stephen L. Mayo, PhD
- Independent Director
- 463.99K
- Elizabeth Barrett
- Independent Director
- 476.43K
- Todd B. Sisitsky
- Independent Director
- --
- David Bonderman
- Lead Independent Director
- --
- Dr. Franz Bernard Humer, PhD
- Independent Director
- 585.00K
- Dr. Vicki L. Sato, PhD
- Independent Director
- 478.79K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data